What are these new drugs?
First off the mark was lecanemab, which in a global clinical study of 1,795 participants with early Alzheimer’s Disease (AD), reportedly held back the rate of cognitive decline – the loss of memory and thinking skills – by 27% and slowed down the decline in quality of life by up to 56%. It was first approved for use in the US as a treatment for early AD in January 2023.